Back to resultsEffect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome
Primary Purpose
Periodontal Diseases, Chronic Periodontitis, Periodontal Pocket
Status
Completed
Phase
Not Applicable
Locations
Japan
Study Type
Interventional
Intervention
IQOS
Cigarette
Sponsored by
About this trial
This is an interventional other trial for Periodontal Diseases focused on measuring Oral Health, Smoking, Cigarette, Reduced risk product, Tobacco heating system, THS, Modified risk tobacco product, Clinical attachment level
Eligibility Criteria
Main Inclusion Criteria:
- Patient is aged ≥ 30 years old.
- Patient has smoked on average at least 10 commercially available cigarettes per day for at least 5 years
- Patient has generalized chronic periodontitis (i.e., more than 30% of diseased teeth with a PD ≥ 4 mm).
Main Exclusion Criteria:
- Patient has self-reported history of diagnosed systemic diseases (e.g., stroke or acute cardiovascular event within the last 5 years, diabetes, active cancer).
- Patient received root planing therapy within the 6 months prior to Visit 1.
- Patient received surgical periodontal therapy within 3 years prior to Visit
- Patient was treated within the 3 months prior to Visit 1 with systemic antibiotics or was treated with topical antibiotics applied in the mouth.
- Continuous systemic use of steroidal or non-steroidal anti-inflammatory drugs for more than 20 days during the past 30-day period (except for low dose aspirin, i.e., ≤300 mg).
- Female patients who are pregnant, breast-feeding, or planning a pregnancy within the course of the study.
Sites / Locations
- Mase Dental Clinic
- Tsudanuma Olive Dental Clinic
- Matsunobu Dental Office
- Taniguchi Dental Clinic
- Takano Dental Clinic
- Tsukuba Healthcare Dental Clinic
- AOI Universal Hospital
- Yoshinaga Dental Office
- Yoshino Dental Clinic
- Saida Dental Clinic
- Sakai Dental Clinic
- Kudan Dental Clinic
- Yano Dental Clinic
- Nikaido Dental Clinic
- Mune Dental Clinic
- Kikuchi Dental Clinic
- Miyata Dental Clinic
- Kato Dental Clinic
- Kimura Dental Clinic
- Yamashita Dental Office
- Yasumasu Dental Office
- Tsukiyama Dental Clinic
- Yoshida Shigeru Dental Office
- Yamashita Dental Clinic
- Heart Dental Clinic
- Higashi Dental Office
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
IQOS arm
Cigarette arm
Arm Description
~86 patients, switching from cigarette smoking to IQOS use.
~86 patients, continuing cigarette smoking.
Outcomes
Primary Outcome Measures
Periodontal Pocket Depth (PD) Change From Baseline at 6 Months
Pocket depth (PD) is the distance from the gingival margin to which a probe penetrates into the pocket. Mean Periodontal PD change from baseline will be measured in all sites with initial PD ≥ 4 mm, following mechanical periodontal therapy, in patients who switch to IQOS use compared to those who continue cigarette smoking.
Secondary Outcome Measures
Periodontal Pocket Depth (PD) Change Over Time. (Mean PD in All Subjects With Initial PD ≥ 4 mm)
Pocket depth (PD) is the distance from the gingival margin to which a probe penetrates into the pocket. Mean Periodontal PD change from baseline will be measured in all sites with initial PD ≥ 4 mm, following mechanical periodontal therapy, in patients who switch to IQOS use compared to those who continue cigarette smoking.
Clinical Attachment Level (CAL) Change Over Time (Mean CAL in All Subjects With Initial PD ≥ 4 mm)
Clinical attachment level (CAL) is the measured distance from cementoenamel junction (CEJ) to the bottom of pocket using a periodontal probe. Mean CAL change from baseline will be measured in sites with initial PD ≥ 4 mm, following mechanical periodontal therapy, in patients who switch to IQOS use compared to those who continue cigarette smoking.
Periodontal Pocket Depth (PD) Change Over Time. (Mean PD in All Subjects With Initial PD ≥ 4 mm) - Descriptive Statistics
Pocket depth (PD) is the distance from the gingival margin to which a probe penetrates into the pocket. Mean Periodontal PD change from baseline will be measured in all sites with initial PD ≥ 4 mm, following mechanical periodontal therapy, in patients who switch to IQOS use compared to those who continue cigarette smoking.
Clinical Attachment Level (CAL) Change Over Time (Mean CAL in All Subjects With Initial PD ≥ 4 mm) - Descriptive Statistics
Clinical attachment level (CAL) is the measured distance from cementoenamel junction (CEJ) to the bottom of pocket using a periodontal probe. Mean CAL change from baseline will be measured in sites with initial PD ≥ 4 mm, following mechanical periodontal therapy, in patients who switch to IQOS use compared to those who continue cigarette smoking.
Full-mouth Periodontal PD Change Over Time.
Pocket depth (PD) is the distance from the gingival margin to which a probe penetrates into the pocket. Change in mean full-mouth PD will be measured, following mechanical periodontal therapy, in patients who switch to IQOS use compared to those who continue cigarette smoking.
Full-mouth Clinical Attachment Level (CAL) Over Time.
Clinical attachment level (CAL) is the measured distance from cementoenamel junction (CEJ) to the bottom of pocket using a periodontal probe. Change in mean full-mouth CAL will be measured, following mechanical periodontal therapy, in patients who switch to IQOS use compared to those who continue cigarette smoking.
Peridontal PD Reduction.
Pocket depth (PD) is the distance from the gingival margin to which a probe penetrates into the pocket. Mean PD change will be measured in sites with initial PD < 4 mm, and with initial PD of 4 mm to <5 mm, 5 mm to < 6 mm, 6 mm to < 7 mm and ≥ 7 mm.
Clinical Attachment Level Improvement
Clinical attachment level (CAL) is the measured distance from cementoenamel junction (CEJ) to the bottom of pocket using a periodontal probe. Mean CAL change will be measured in sites with initial PD < 4 mm, and with initial PD of 4 mm to <5 mm, 5 mm to < 6 mm, 6 mm to < 7 mm and ≥ 7 mm.
Number of Periodontally Diseased Sites.
Pocket depth (PD) is the distance from the gingival margin to which a probe penetrates into the pocket. Any change will be recorded in the number of periodontally diseased sites with Pocket Depth (PD) < 4 mm, with PD 4 mm to < 5mm, with PD 5 mm to < 6 mm , with PD 6 mm to < 7 mm and with PD ≥ 7 mm. PD is the distance from the gingival margin to which a probe penetrates into the pocket.
Gingival Inflammation
Gingival inflammation will be measured by calculating the gingival index (GI) score for each target tooth.
The gingival index (GI) scores each site on a 0 to 3 scale, with 0 being normal and 3 being severe inflammation characterized by edema, redness, swelling, and spontaneous bleeding.
Tooth Mobility
Tooth mobility will be graded according to Miller's mobility index (MMI), which is the most widely accepted method for routine clinical examinations of tooth mobility. The tooth is held between the metallic handles of two instruments and moved in the buccolingual or buccopalatal direction, and the moved distance is visually estimated by the person conducting the examination.
Grade 0: Physiologic movement within 0.2 mm; Grade 1: Slight mobility, tooth can be moved 0.2 - 1 mm labiolingually; Grade 2: Moderate mobility, tooth can be moved 1 - 2 mm labiolingually or mesiodistally; Grade 3: Severe mobility, tooth can be moved more than 2 mm labiolingually or mesiodistally, or ability to depress the tooth in a vertical direction.
Presence of Plaque on Tooth Surfaces in Full Mouth
Plaque will be measured using the plaque control record (PCR) percentage.
Inflammatory Status in Periodontal Pockets
Gum inflammation was measured using percentage of teeth bleeding on probing (BOP).
BOP in full mouth was measured to assess inflammatory status in the pocket and was assessed as YES or NO of bleeding at 6 sites per tooth. Gently probing (approximately 20 g pressure), the bleeding site within 30 seconds was assessed as YES.
Concentrations of Urinary Nicotine Equivalents (NEQ)
This biomarker of exposure to a tobacco smoke constituent will be measured in patients who switch to IQOS use and patients who continue cigarette smoking. Concentrations measured in urine and expressed as concentration adjusted for creatinine (mg/g creat).
Concentrations of Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (Total NNAL)
This biomarker of exposure to a tobacco smoke constituent will be measured in patients who switch to IQOS use and patients who continue cigarette smoking. Concentrations measured in urine and expressed as concentration adjusted for creatinine (pg/mg creat).
Concentrations of 2-cyanoethylmercapturic Acid (CEMA)
This biomarker of exposure to a tobacco smoke constituent will be measured in patients who switch to IQOS use and patients who continue cigarette smoking. Concentrations measured in urine and expressed as concentration adjusted for creatinine (ng/mg creat).
Use of Tobacco or Nicotine-containing Products in Patients Switching to IQOS Use and Patients Who Continue Cigarette Smoking.
Self-reported use of tobacco or nicotine containing products will be measured over the study in patients switching to IQOS use and patients who continue cigarette smoking.
Full Information
NCT ID
NCT03364751
First Posted
November 23, 2017
Last Updated
January 26, 2023
Sponsor
Philip Morris Products S.A.
1. Study Identification
Unique Protocol Identification Number
NCT03364751
Brief Title
Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome
Official Title
A 6-month Randomized, Controlled, Open-label, 2-arm Parallel Group, Multicenter Study to Evaluate the Effect of Switching From Cigarette Smoking to the Use of IQOS in Smokers With Generalized Chronic Periodontitis on the Response to Mechanical Periodontal Treatment and Oral Health Status.
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Completed
Study Start Date
November 7, 2017 (Actual)
Primary Completion Date
December 21, 2018 (Actual)
Study Completion Date
June 12, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Philip Morris Products S.A.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study was to demonstrate in patients with generalized chronic periodontitis that switching from cigarette smoking to using IQOS improves the response to periodontal therapy and the overall oral health status compared to continuing cigarette smoking.
Note: "IQOS" is the Tobacco Heating System (THS) with Marlboro Heatsticks, marketed in Japan under the brand name IQOS
Detailed Description
This was a randomized, controlled, open-label, 2-arm, parallel group ambulatory study with the randomization stratified by daily cigarette consumption over the month (30 days) prior to Visit 1 (10-19 cigarettes/day vs. > 19 cigarettes/day) and disease severity recorded at Visit 1 (< 5 mm Pocket Depth [PD] vs. ≥ 5 mm PD) based on the most severely diseased tooth, in smokers with generalized chronic periodontitis who are randomized to either switch from cigarette smoking to IQOS use or continuing cigarette smoking.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Periodontal Diseases, Chronic Periodontitis, Periodontal Pocket, Tooth Mobility, Gingival Diseases, Smoking, Cigarette
Keywords
Oral Health, Smoking, Cigarette, Reduced risk product, Tobacco heating system, THS, Modified risk tobacco product, Clinical attachment level
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Investigator
Masking Description
The Dentist (Investigator) or Dental Hygienist performing the periodontal assessments will be blinded to the arm allocation.
Allocation
Randomized
Enrollment
179 (Actual)
8. Arms, Groups, and Interventions
Arm Title
IQOS arm
Arm Type
Active Comparator
Arm Description
~86 patients, switching from cigarette smoking to IQOS use.
Arm Title
Cigarette arm
Arm Type
Active Comparator
Arm Description
~86 patients, continuing cigarette smoking.
Intervention Type
Other
Intervention Name(s)
IQOS
Intervention Description
Patients will switch from cigarette smoking to ad libitum IQOS use.
Intervention Type
Other
Intervention Name(s)
Cigarette
Intervention Description
Patients will continue to smoke cigarettes ad libitum.
Primary Outcome Measure Information:
Title
Periodontal Pocket Depth (PD) Change From Baseline at 6 Months
Description
Pocket depth (PD) is the distance from the gingival margin to which a probe penetrates into the pocket. Mean Periodontal PD change from baseline will be measured in all sites with initial PD ≥ 4 mm, following mechanical periodontal therapy, in patients who switch to IQOS use compared to those who continue cigarette smoking.
Time Frame
At 6 months
Secondary Outcome Measure Information:
Title
Periodontal Pocket Depth (PD) Change Over Time. (Mean PD in All Subjects With Initial PD ≥ 4 mm)
Description
Pocket depth (PD) is the distance from the gingival margin to which a probe penetrates into the pocket. Mean Periodontal PD change from baseline will be measured in all sites with initial PD ≥ 4 mm, following mechanical periodontal therapy, in patients who switch to IQOS use compared to those who continue cigarette smoking.
Time Frame
At 3 months
Title
Clinical Attachment Level (CAL) Change Over Time (Mean CAL in All Subjects With Initial PD ≥ 4 mm)
Description
Clinical attachment level (CAL) is the measured distance from cementoenamel junction (CEJ) to the bottom of pocket using a periodontal probe. Mean CAL change from baseline will be measured in sites with initial PD ≥ 4 mm, following mechanical periodontal therapy, in patients who switch to IQOS use compared to those who continue cigarette smoking.
Time Frame
At 3 months and 6 months
Title
Periodontal Pocket Depth (PD) Change Over Time. (Mean PD in All Subjects With Initial PD ≥ 4 mm) - Descriptive Statistics
Description
Pocket depth (PD) is the distance from the gingival margin to which a probe penetrates into the pocket. Mean Periodontal PD change from baseline will be measured in all sites with initial PD ≥ 4 mm, following mechanical periodontal therapy, in patients who switch to IQOS use compared to those who continue cigarette smoking.
Time Frame
From baseline to 3 months and 6 months
Title
Clinical Attachment Level (CAL) Change Over Time (Mean CAL in All Subjects With Initial PD ≥ 4 mm) - Descriptive Statistics
Description
Clinical attachment level (CAL) is the measured distance from cementoenamel junction (CEJ) to the bottom of pocket using a periodontal probe. Mean CAL change from baseline will be measured in sites with initial PD ≥ 4 mm, following mechanical periodontal therapy, in patients who switch to IQOS use compared to those who continue cigarette smoking.
Time Frame
From baseline to 3 months and 6 months
Title
Full-mouth Periodontal PD Change Over Time.
Description
Pocket depth (PD) is the distance from the gingival margin to which a probe penetrates into the pocket. Change in mean full-mouth PD will be measured, following mechanical periodontal therapy, in patients who switch to IQOS use compared to those who continue cigarette smoking.
Time Frame
From baseline to 3 months and 6 months
Title
Full-mouth Clinical Attachment Level (CAL) Over Time.
Description
Clinical attachment level (CAL) is the measured distance from cementoenamel junction (CEJ) to the bottom of pocket using a periodontal probe. Change in mean full-mouth CAL will be measured, following mechanical periodontal therapy, in patients who switch to IQOS use compared to those who continue cigarette smoking.
Time Frame
From baseline to 3 months and 6 months
Title
Peridontal PD Reduction.
Description
Pocket depth (PD) is the distance from the gingival margin to which a probe penetrates into the pocket. Mean PD change will be measured in sites with initial PD < 4 mm, and with initial PD of 4 mm to <5 mm, 5 mm to < 6 mm, 6 mm to < 7 mm and ≥ 7 mm.
Time Frame
From baseline to 3 months and 6 months
Title
Clinical Attachment Level Improvement
Description
Clinical attachment level (CAL) is the measured distance from cementoenamel junction (CEJ) to the bottom of pocket using a periodontal probe. Mean CAL change will be measured in sites with initial PD < 4 mm, and with initial PD of 4 mm to <5 mm, 5 mm to < 6 mm, 6 mm to < 7 mm and ≥ 7 mm.
Time Frame
From baseline to 3 months and 6 months
Title
Number of Periodontally Diseased Sites.
Description
Pocket depth (PD) is the distance from the gingival margin to which a probe penetrates into the pocket. Any change will be recorded in the number of periodontally diseased sites with Pocket Depth (PD) < 4 mm, with PD 4 mm to < 5mm, with PD 5 mm to < 6 mm , with PD 6 mm to < 7 mm and with PD ≥ 7 mm. PD is the distance from the gingival margin to which a probe penetrates into the pocket.
Time Frame
From baseline to 3 months and 6 months
Title
Gingival Inflammation
Description
Gingival inflammation will be measured by calculating the gingival index (GI) score for each target tooth.
The gingival index (GI) scores each site on a 0 to 3 scale, with 0 being normal and 3 being severe inflammation characterized by edema, redness, swelling, and spontaneous bleeding.
Time Frame
From baseline to 3 months and 6 months
Title
Tooth Mobility
Description
Tooth mobility will be graded according to Miller's mobility index (MMI), which is the most widely accepted method for routine clinical examinations of tooth mobility. The tooth is held between the metallic handles of two instruments and moved in the buccolingual or buccopalatal direction, and the moved distance is visually estimated by the person conducting the examination.
Grade 0: Physiologic movement within 0.2 mm; Grade 1: Slight mobility, tooth can be moved 0.2 - 1 mm labiolingually; Grade 2: Moderate mobility, tooth can be moved 1 - 2 mm labiolingually or mesiodistally; Grade 3: Severe mobility, tooth can be moved more than 2 mm labiolingually or mesiodistally, or ability to depress the tooth in a vertical direction.
Time Frame
From baseline to 3 months and 6 months
Title
Presence of Plaque on Tooth Surfaces in Full Mouth
Description
Plaque will be measured using the plaque control record (PCR) percentage.
Time Frame
From baseline to 3 months and 6 months
Title
Inflammatory Status in Periodontal Pockets
Description
Gum inflammation was measured using percentage of teeth bleeding on probing (BOP).
BOP in full mouth was measured to assess inflammatory status in the pocket and was assessed as YES or NO of bleeding at 6 sites per tooth. Gently probing (approximately 20 g pressure), the bleeding site within 30 seconds was assessed as YES.
Time Frame
From baseline to 3 months and 6 months
Title
Concentrations of Urinary Nicotine Equivalents (NEQ)
Description
This biomarker of exposure to a tobacco smoke constituent will be measured in patients who switch to IQOS use and patients who continue cigarette smoking. Concentrations measured in urine and expressed as concentration adjusted for creatinine (mg/g creat).
Time Frame
From baseline to 3 months and 6 months
Title
Concentrations of Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (Total NNAL)
Description
This biomarker of exposure to a tobacco smoke constituent will be measured in patients who switch to IQOS use and patients who continue cigarette smoking. Concentrations measured in urine and expressed as concentration adjusted for creatinine (pg/mg creat).
Time Frame
From baseline to 3 months and 6 months
Title
Concentrations of 2-cyanoethylmercapturic Acid (CEMA)
Description
This biomarker of exposure to a tobacco smoke constituent will be measured in patients who switch to IQOS use and patients who continue cigarette smoking. Concentrations measured in urine and expressed as concentration adjusted for creatinine (ng/mg creat).
Time Frame
From baseline to 3 months and 6 months
Title
Use of Tobacco or Nicotine-containing Products in Patients Switching to IQOS Use and Patients Who Continue Cigarette Smoking.
Description
Self-reported use of tobacco or nicotine containing products will be measured over the study in patients switching to IQOS use and patients who continue cigarette smoking.
Time Frame
From baseline to 6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Main Inclusion Criteria:
Patient is aged ≥ 30 years old.
Patient has smoked on average at least 10 commercially available cigarettes per day for at least 5 years
Patient has generalized chronic periodontitis (i.e., more than 30% of diseased teeth with a PD ≥ 4 mm).
Main Exclusion Criteria:
Patient has self-reported history of diagnosed systemic diseases (e.g., stroke or acute cardiovascular event within the last 5 years, diabetes, active cancer).
Patient received root planing therapy within the 6 months prior to Visit 1.
Patient received surgical periodontal therapy within 3 years prior to Visit
Patient was treated within the 3 months prior to Visit 1 with systemic antibiotics or was treated with topical antibiotics applied in the mouth.
Continuous systemic use of steroidal or non-steroidal anti-inflammatory drugs for more than 20 days during the past 30-day period (except for low dose aspirin, i.e., ≤300 mg).
Female patients who are pregnant, breast-feeding, or planning a pregnancy within the course of the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christelle Haziza, PhD
Organizational Affiliation
Philip Morris Products S.A.
Official's Role
Study Chair
Facility Information:
Facility Name
Mase Dental Clinic
City
Futtsu
State/Province
Chiba
ZIP/Postal Code
293-0001
Country
Japan
Facility Name
Tsudanuma Olive Dental Clinic
City
Narashino
State/Province
Chiba
ZIP/Postal Code
275-0016
Country
Japan
Facility Name
Matsunobu Dental Office
City
Miyako
State/Province
Fukuoka
ZIP/Postal Code
800-0323
Country
Japan
Facility Name
Taniguchi Dental Clinic
City
Sapporo
State/Province
Hokkaido
ZIP/Postal Code
003-0023
Country
Japan
Facility Name
Takano Dental Clinic
City
Chikusei
State/Province
Ibaraki
ZIP/Postal Code
308- 0031
Country
Japan
Facility Name
Tsukuba Healthcare Dental Clinic
City
Tsukuba
State/Province
Ibaraki
ZIP/Postal Code
305-0834
Country
Japan
Facility Name
AOI Universal Hospital
City
Kawasaki
State/Province
Kanagawa
ZIP/Postal Code
210-0822
Country
Japan
Facility Name
Yoshinaga Dental Office
City
Uki
State/Province
Kumamoto
ZIP/Postal Code
869-0521
Country
Japan
Facility Name
Yoshino Dental Clinic
City
Kawaguchi
State/Province
Saitama
ZIP/Postal Code
332-0016
Country
Japan
Facility Name
Saida Dental Clinic
City
Tokorozawa
State/Province
Saitama
ZIP/Postal Code
359-1146
Country
Japan
Facility Name
Sakai Dental Clinic
City
Bunkyō
State/Province
Tokyo
ZIP/Postal Code
113-0033
Country
Japan
Facility Name
Kudan Dental Clinic
City
Chiyoda
State/Province
Tokyo
ZIP/Postal Code
102-0074
Country
Japan
Facility Name
Yano Dental Clinic
City
Chōfu
State/Province
Tokyo
ZIP/Postal Code
182-0024
Country
Japan
Facility Name
Nikaido Dental Clinic
City
Chūō
State/Province
Tokyo
ZIP/Postal Code
103-0027
Country
Japan
Facility Name
Mune Dental Clinic
City
Setagaya
State/Province
Tokyo
ZIP/Postal Code
157-0072
Country
Japan
Facility Name
Kikuchi Dental Clinic
City
Shinjuku
State/Province
Tokyo
ZIP/Postal Code
160-0023
Country
Japan
Facility Name
Miyata Dental Clinic
City
Toshima
State/Province
Tokyo
ZIP/Postal Code
171-0043
Country
Japan
Facility Name
Kato Dental Clinic
City
Himi
State/Province
Toyama
ZIP/Postal Code
935-0015
Country
Japan
Facility Name
Kimura Dental Clinic
City
Fukuoka
ZIP/Postal Code
810-0001
Country
Japan
Facility Name
Yamashita Dental Office
City
Fukuoka
ZIP/Postal Code
810-0001
Country
Japan
Facility Name
Yasumasu Dental Office
City
Fukuoka
ZIP/Postal Code
810-0001
Country
Japan
Facility Name
Tsukiyama Dental Clinic
City
Fukuoka
ZIP/Postal Code
811-1302
Country
Japan
Facility Name
Yoshida Shigeru Dental Office
City
Fukuoka
ZIP/Postal Code
812-0011
Country
Japan
Facility Name
Yamashita Dental Clinic
City
Kagoshima
ZIP/Postal Code
890-0053
Country
Japan
Facility Name
Heart Dental Clinic
City
Kagoshima
ZIP/Postal Code
892-0844
Country
Japan
Facility Name
Higashi Dental Office
City
Kumamoto
ZIP/Postal Code
860-0855
Country
Japan
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
33459599
Citation
Pouly S, Ng WT, Benzimra M, Soulan A, Blanc N, Zanetti F, Picavet P, Baker G, Haziza C. Effect of Switching to the Tobacco Heating System Versus Continued Cigarette Smoking on Chronic Generalized Periodontitis Treatment Outcome: Protocol for a Randomized Controlled Multicenter Study. JMIR Res Protoc. 2021 Jan 18;10(1):e15350. doi: 10.2196/15350.
Results Reference
background
Citation
Effect of switching from cigarette smoking to the use of the tobacco heating system on periodontitis treatment outcome: Periodontal parameter results from a multicenter Japanese study Authors: Pouly, Sandrine; Ng, Wee Teck; Blanc, Nicolas; Hession, Paul; Zanetti, Filippo; Battey, James N. D.; de La Bourdonnaye, Guillaume; Heremans, Annie; Haziza, Christelle Journal Title: Frontiers in dental medicine Publication Date: 7/22/2022 Volume: 3 DOI: 10.3389/fdmed.2022.915079
Results Reference
result
Learn more about this trial
Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome
We'll reach out to this number within 24 hrs